Evaluation of novel highly specific antibodies to cancer testis antigen Centrin‐1 for radioimmunoimaging and radioimmunotherapy of pancreatic cancer

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) accounts for >90% of pancreatic malignancies, and has median survival of <6 months. There is an urgent need for diagnostic and therapeutic options for PDAC. Centrin1 (CETN1) is a novel member of Cancer/Testis Antigens, with a 25‐fold increase...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiao, Rubin, Allen, Kevin J. H., Malo, Mackenzie E., Helal, Muath, Jiang, Zewei, Smart, Karishma, Buhl, Susan V., Rickles, David, Bryan, Ruth A., Dadachova, Ekaterina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718527/
https://www.ncbi.nlm.nih.gov/pubmed/31309741
http://dx.doi.org/10.1002/cam4.2379

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718527/
https://www.ncbi.nlm.nih.gov/pubmed/31309741
http://dx.doi.org/10.1002/cam4.2379

Ejemplares similares